FRANKFURT Oct 5 Stada, the German generic drugmaker whose chairman was ousted by disgruntled investors, said it was banking on branded products to underpin longer term growth.
The company said on Wednesday that its target of group sales of 5 percent on average per year until 2019 would be driven by 8 percent growth per year at the branded products business, which makes brand-name prescription drugs that have lost patent protection as well as branded non-prescription drugs.
Stada is making presentations on its growth prospects to investors on Wednesday.
Stada's non-branded generic drugs business, which still accounted for about 60 percent of group sales last year, would see revenue increase by about 3 percent per year through 2019, it added.
Stada issued new earnings targets for 2019 in July.
(Reporting by Ludwig Burger; Editing by Harro ten Wolde)
Aixtron, Fujian to explore what is left of deal after U.S. veto
FRANKFURT, Dec 3 German semiconductor equipment maker Aixtron will explore with its Chinese suitor what can be salvaged of the planned takeover after a U.S. presidential order ruled the deal posed a national security risk, the company said on Saturday.
UPDATE 2-Trump moves to quickly fill his top Cabinet ranks
NEW YORK, Dec 2 U.S. President-elect Donald Trump said he expected to have most members of his Cabinet announced next week, interviewing more candidates at Trump Tower for top jobs in his administration as he prepares to take office on Jan. 20.